ATL relies on natural uptake to deliver ATL1102 to immune cells that play a role in the inflammatory muscle damage and is used at a low 25mg/week sc doses (0.4mg/kg) i.e 100x lower dose
. Keeping muscle intact with ATL1102 may enable better outcome with dystrophin producing drugs and this is to be tested for in animal studies. ———— Itsa: : Does not see PGN-ED051 (PepGen)and Sareptas SRP 5051 as a threat to Atl1102 for DMD.and am confident Atl1102 will capture 100% of the DMD market.
If the combination study in animals ( delay in getting the right type of mice ) proves efficacy “Game Over” Sarepta will want part of the action $$$
This is why Itsa is confident that $$$ 70/100 million will not be a problem come futility…
I keep on saying imo this is a $5 minimum stock Just on Non Ambulant boys $4 billion Ambulant boys $6 billion ( market by 2030) like Mac9 says… earnings x10 ( conservative) Mind blowing… and people you can pick up shares @13c…crazy
Add to this all Anp has to achieve is the same endpoints as the last DMD trial in Australia. Boom!!! Commercialisation $$
ANP Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
